LEO Pharma Inc. cordially invites you to participate in a professional non-CME program

A treatment for adults with uncontrolled moderate-to-severe atopic dermatitis

Adbry™ (tralokinumab-ldrm)

The first and only biologic developed to specifically bind to and inhibit the IL-13 cytokine

Please see enclosed Full Indication and Important Safety Information and accompanying Prescribing Information.

Adbry™ (tralokinumab-ldrm) Injection 150 mg/mL

Adrian O. Rodriguez, MD, FAAD

Nashville Skin: Comprehensive Dermatology Center
Nashville, TN
Clinical Faculty University of Tennessee Health Science Center
Nashville, TN

Dr. Rodriguez is a consultant of LEO Pharma Inc.

DATE: November 6, 2022

TIME: 7:00 AM

VENUE: Woodlands Hotel & Suites
105 Visitor Center Dr.
Williamsburg, VA 23185

PROGRAM OVERVIEW

During this presentation, we will review atopic dermatitis pathophysiology and highlight a key driver of the underlying inflammation. We will then discuss a treatment option for moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled.

THANK YOU FOR YOUR INTEREST IN THIS PROGRAM

This promotional program is sponsored by LEO Pharma Inc. No CME/CE credit will be provided. In accordance with PhRMA Guidelines, only physicians and healthcare professionals involved in providing patient care or product recommendations may attend this informative program. Attendance by guests or spouses is not permitted. No alcohol is provided at this program. This invitation is intended for the recipient only and is non-transferable.

Please note: Your name and the value of any meal/refreshment will be reported as required by federal and state laws. You must notify the LEO Pharma representative upon sign-in if you maintain a license to practice medicine in Minnesota or Vermont.

INDICATION

ADBRY™ (tralokinumab-ldrm) injection is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

ADBRY is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in ADBRY.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis and angioedema have occurred after administration of ADBRY. If a serious hypersensitivity reaction occurs, discontinue ADBRY immediately and initiate appropriate therapy.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received ADBRY. Conjunctivitis was the most frequently reported eye disorder. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Parasitic (Helminth) Infections: Treat patients with pre-existing helminth infections before initiating treatment with ADBRY. If patients become infected while receiving ADBRY and do not respond to antihelminth treatment, discontinue treatment with ADBRY until the infection resolves.

Risk of Infection with Live Vaccines: ADBRY may alter a patient's immunity and increase the risk of infection following administration of live vaccines. Prior to initiating therapy with ADBRY, complete all age appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients treated with ADBRY. Limited data are available regarding coadministration of ADBRY with non-live vaccines.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥1%) are upper respiratory infections, conjunctivitis, injection site reactions, and eosinophilia.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are limited data from the use of ADBRY in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, ADBRY may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence of tralokinumab-ldrm in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is present in breast milk. The effects of local gastrointestinal exposure and limited systemic exposure to ADBRY on the breastfed infant are unknown.

Pediatric Use: The safety and effectiveness of ADBRY have not been established in pediatric patients.

Please see full Prescribing Information.

For more information, visit **AdbryHCP.com**

Adbry™ (tralokinumab-ldrm) Injection 150 mg/mL

The LEO Pharma logo is a registered trademark of LEO Pharma A/S.
Adbry™ is a trademark of LEO Pharma A/S.

© 2022 LEO Pharma Inc. All rights reserved.

MAT-57594 | June 2022